Head to Head Review: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Cyclo Therapeutics (NASDAQ:CYTH)

Cyclo Therapeutics (NASDAQ:CYTH) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cyclo Therapeutics and Eloxx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclo Therapeutics	0	2	1	0	2.33
Eloxx Pharmaceuticals	0	0	0	0	0.00

Cyclo Therapeutics presently has a consensus price target of $0.95, suggesting a potential upside of 31.94%. Given Cyclo Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cyclo Therapeutics is more favorable than Eloxx Pharmaceuticals.

Profitability

This table compares Cyclo Therapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclo Therapeutics	-2,847.19%	-28,686.89%	-278.54%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Institutional and Insider Ownership

68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Cyclo Therapeutics and Eloxx Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclo Therapeutics	$1.08 million	19.13	-$20.06 million	($0.90)	-0.80
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	($9.07)	N/A

Cyclo Therapeutics has higher revenue and earnings than Eloxx Pharmaceuticals. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cyclo Therapeutics has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.63, suggesting that its share price is 163% more volatile than the S&P 500.

Summary

Cyclo Therapeutics beats Eloxx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.